Almirall (FRA:E2Z) Gross-Profit-to-Asset % : 27.10% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Almirall Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Almirall's annualized Gross Profit for the quarter that ended in Mar. 2024 was €634.4 Mil. Almirall's average Total Assets over the quarter that ended in Mar. 2024 was €2,341.1 Mil. Therefore, Almirall's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 27.10%.

Almirall Gross-Profit-to-Asset % Historical Data

The historical data trend for Almirall's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Gross-Profit-to-Asset % Chart

Almirall Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

63.13

26.80

29.58

30.92

30.16

Almirall Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	28.50	37.40	-	27.10

Competitive Comparison of Almirall's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Almirall's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Almirall's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Almirall's Gross-Profit-to-Asset % falls into.

Almirall Gross-Profit-to-Asset % Calculation

Almirall's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	682.037	/	( (2147.691	+	2374.985)	/ 2 )
	=	682.037	/	2261.338
	=	30.16 %

Almirall's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	634.4	/	( (2374.985	+	2307.2)	/ 2 )
	=	634.4	/	2341.0925
	=	27.10 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Almirall Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Almirall's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Almirall (FRA:E2Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (FRA:E2Z) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

LBTSF:USA 0O9B:UK ALM:Spain E2Z:Germany

Address

Ronda General Mitre 151, Barcelona, ESP, 08022

Website

http://www.almirall.es

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (FRA:E2Z) Headlines

No Headlines